308 related articles for article (PubMed ID: 2826586)
1. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
2. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
Servis C; Lambris JD
J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
4. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
5. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
6. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM.
Carter RH; Fearon DT
J Immunol; 1989 Sep; 143(6):1755-60. PubMed ID: 2528579
[TBL] [Abstract][Full Text] [Related]
7. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
8. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
[TBL] [Abstract][Full Text] [Related]
9. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
10. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.
Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C
J Immunol; 1991 Mar; 146(6):1766-72. PubMed ID: 1826011
[TBL] [Abstract][Full Text] [Related]
12. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
Tedder TF; Goldmacher VS; Lambert JM; Schlossman SF
J Immunol; 1986 Aug; 137(4):1387-91. PubMed ID: 3016095
[TBL] [Abstract][Full Text] [Related]
14. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
[TBL] [Abstract][Full Text] [Related]
15. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
16. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
18. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
19. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
